USATODAY.com - Study finds raloxifene safer than tamoxifen for breast cancer: "A widely used osteoporosis drug is safer and just as effective reducing invasive breast cancer risk as tamoxifen, the only drug now approved for that use, say long-awaited data released Monday from a trial of nearly 20,000 women.

After an average of four years of treatment, both raloxifene and tamoxifen cut the risk by about 50%, say researchers with the Study of Tamoxifen and Raloxifene, or STAR. "